Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats

ÇOLAK, SUAT; Çığşar, Gülşen; ÜNAL, Bünyami; keleş, osman nuri; HALICI, Mesut Bünyamin; BİLGİN, Bülent Çağlar; ERDEMCİ, Burak; Erol, Huseyin Serkan; AKARAS, Nurhan; CAN, Serpil; Can, Dr İsmail

Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats

Osman Nuri KELEŞ, (Atatürk Üniversitesi, Tıp Fakültesi, Histoloji ve Embriyoloji Anabilim Dalı, Erzurum, Türkiye)

Serpil CAN, (Kafkas Üniversitesi, Tıp Fakültesi, Fizyoloji Anabilim Dalı, Kars, Türkiye)

Gülşen ÇIĞŞAR, (Kafkas Üniversitesi, Tıp Fakültesi, Acil Bölümü, Kars, Türkiye)

Suat ÇOLAK, (Artvin Çoruh Üniversitesi, Fen Edebiyat Fakültesi, Biyoloji Bölümü, Artvin, Türkiye)

Hüseyin Serkan EROL, (Atatürk Üniversitesi, Veteriner Fakültesi, Biyokimya Ana Bilim Dalı, Erzurum, Türkiye)

Nurhan AKARAS, (Atatürk Üniversitesi, Tıp Fakültesi, Histoloji ve Embriyoloji Anabilim Dalı, Erzurum, Türkiye)

Burak ERDEMCİ, (Atatürk Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi, Bölümü, Erzurum, Türkiye)

Bülent Çağlar BİLGİN, (Kafkas Üniversitesi, Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, Kars, Türkiye)

İsmail CAN, (Kafkas Üniversitesi, Tıp Fakültesi, Histoloji ve Embriyoloji Bölümü, Kars, Türkiye)

Bünyami ÜNAL, (Atatürk Üniversitesi, Tıp Fakültesi, Histoloji ve Embriyoloji Anabilim Dalı, Erzurum, Türkiye)

Mesut Bünyamin HALICI, (Atatürk Üniversitesi, Veteriner Fakültesi, Biyokimya Ana Bilim Dalı, Erzurum, Türkiye)

Diğer Yazarlar

Kafkas Üniversitesi Veteriner Fakültesi Dergisi

2 0

Yıl: 2014 Cilt: 20 Sayı: 6 Sayfa Aralığı: 929 - 938 Metin Dili: Diğer İndeks Tarihi: 29-07-2022

Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats

Öz:

Bu çalışmanın amacı, relaps multiple miyelom tedavi etmek için kullanılan ilk terapötik proteazom inhibitörü olan bortezomibinkaraciğer üzerine immunohistokimyasal, histopatolojik ve biyokimyasal etkilerini araştırmak ve bir antioksidant ve doku koruyucuajan olarak B-1,3-(D)-glukanın etkilerini değerlendirmekdi. Deney; kontrol (sağlıklı), bortezomib ile tedavi, B-1,3-(D)-glukan iletedavi ve bortezomib + B-1,3-(D)-glukan ile tedavi olmak üzere dört tedavi grubuna bölünen 36 yetişkin erkek sıçan içerdi. Her birgrup sakrifikasyon zamanına (48 veya 72 saat) göre iki alt gruba ayrıldı. Deneylerin bitiminden sonra, süperoksit dismutaz (SOD)aktivitesi ve lipid peroksidasyon (LPO) miktarları ölçüldü ve tüm sıçan karaciğer dokularında immünohistokimyasal ve histopatolojikdeğişiklikler incelendi. B-1,3-(D)-glukan ile tedavi LPO değişikliğini normalize etti ve endojen SOD aktivitesi aşırı uyardı. Histopatolojikparametrelerin sonuçları, bortezomib grubunda B-1,3-(D)-glukan ile tedavi NF-kB yoluyla Kupfer hücre aktivasyonunu ve non-spesifikreaktif hepatit (NSRH) gelişimini regüle ettiğini gösterdi. B-1,3-(D)-glukan uygulaması, sıçan karaciğerinde bortezomibin neden olduğugeri döndürülebilir doku hasarında efektifdir.

Anahtar Kelime:

Konular: Veterinerlik

Sıçanlarda bortezomib indüklü karaciğer hasarında B-1,3-(D)-glukan ın hepatoprotektif etkileri

Öz:

The aim of this study was to evaluate the efects of β -1,3-(D)-glucan as an antioxidant and tissue protective agent and studythe biochemical, histopathologic, and immunohistochemical efects of first therapeutic proteasome inhibitor bortezomib on theliver for treating relapsed multiple myeloma. The experiment included 36 adult male rats, which were divided into four treatmentgroups: control (healthy); bortezomib-treated; β-1,3-D-glucan-treated; and bortezomib + β-1,3-(D)-glucan-treated. Each group wassubdivided into two subgroups based on time of sacrifice (48 or 72 h). After the experiments, superoxide dismutase (SOD) activityand lipid peroxidation (LPO) amounts were determined, and immunohistochemical and histopathological changes were examinedin all rat liver tissues. β -1,3-(D)-Glucan treatment normalized changes of LPO and stimulated an over activity of endogenous SOD.The results of the histopathologic parameters showed that treatment with β -1,3-(D)-Glucan in the bortezomib group amelioratedthe development of non-specific reactive hepatitis (NSRH) and Kupfer cell activation via NF-kB. Administration of β -1,3-(D)-Glucan isefective in reversing tissue damage induced by bortezomib in rat livers.

Anahtar Kelime:

Konular: Veterinerlik

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Demasi M, Netto LE, Silva GM, Hand A, de Oliveira CL, Bicev RN, Gozzo F, Barros MH, Leme JM, Ohara E: Redox regulation of the proteasome via S-glutathionylation. Redox Biol, 14 (2): 44-51, 2013.
2. Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, Takayama H, Kikuchi A, Kanamori T, Shima KR, Lan F, Takeda T, Kurita S, Ishikura K, Kita Y, Iwayama K, Kato K, Uno M, Takeshita Y, Yamamoto M, Tokuyama K, Iseki S, Tanaka K, Kaneko S: Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver. Diabetes, 62 (3): 811-824, 2013.
3. Yerlikaya A, Erin N: Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Int J Mol Med, 22 (6): 817-823, 2008.
4. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S: Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer, 7 (40): 1-14, 2008.
5. Voorhees PM, Dees EC, ONeil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res, 9 (17): 6316-6325, 2003.
6. Elliott PJ, Zollner TM, Boehncke WH: Proteasome inhibition: A new anti-infammatory strategy. J Mol Med (Berl), 81(4): 235-245, 2003.
7. James SE, Dunham M, Carrion-Jones M, Murashov A, Lu Q: Rho kinase inhibitor Y-27632 facilitates recovery from experimental peripheral neuropathy induced by anti-cancer drug cisplatin. Neurotoxicology, 31 (2): 188-194, 2010.
8. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G: Human metabolism of the proteasome inhibitor bortezomib: Identification of circulating metabolites. Drug Metab Dispos, 33 (6): 771-777, 2005.
9. Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, Takayama H, Kikuchi A, Kanamori T, Shima KR, Lan F, Takeda T, Kurita S, Ishikura K, Kita Y, Iwayama K, Kato K, Uno M, Takeshita Y, Yamamoto M, Tokuyama K, Iseki S, Tanaka K, Kaneko S: Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver. Diabetes, 62 (3): 811-824, 2013.
10. Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS: Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos, 34 (4): 702-708, 2006.
11. Amin A, Hamza AA: Oxidative stress mediates drug-induced hepatotoxicity in rats: A possible role of DNA fragmentation. Toxicology, 208 (3): 367-375, 2005.
12. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C: Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int J Cancer, 123 (6): 1227-1239, 2008.
13. Karaduman D, Eren B, Keles ON: The protective efect of beta- 1,3-D-glucan on taxol-induced hepatotoxicity: A histopathological and stereological study. Drug Chem Toxicol, 33 (1): 8-16, 2010.
14. Pelizon AC, Kaneno R, Soares AM, Meira DA, Sartori A: Immuno- modulatory activities associated with beta-glucan derived from Saccharomyces cerevisiae. Physiol Res, 54 (5): 557-564, 2005.
15. Samuelsen AB, Schrezenmeir J, Knutsen SH: Efects of orally administered yeast-derived beta-glucans: A review. Mol Nutr Food Res, 58 (1): 183-193, 2014.
16. Brown GD, Gordon S: Immune recognition. A new receptor for beta- glucans. Nature, 413 (6851): 36-37, 2001.
17. Gelderman KA, Tomlinson S, Ross GD, Gorter A: Complement function in mAb-mediated cancer immunotherapy. Trends Immunol, 25 (3): 158-164, 2004.
18. Aydogan MS, Yucel A, Erdogan MA, Polat A, Cetin A, Ucar M, Duran ZR, Colak C, Durmus M: Efects of oral β- glucan on liver ischemia/ reperfusion injury in rats. Transplant Proc , 45 (2): 487-491, 2013.
19. Gomez AM, Vrolix K, Martínez-Martínez P, Molenaar PC, Phernambucq M, van der Esch E, Duimel H, Verheyen F, Voll RE, Manz RA, De Baets MH, Losen M: Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol, 186 (4): 2503-2513, 2011.
20. Sun Y, Larry W.O, Ying L: A simple method for clinical assay of superoxide dismutase. Clin Chem, 34 (3): 497-500, 1988.
21. Ohkawa H, Ohishi H, Yagi K: Assay for lipid peroxide in animal tissues by thiobarbutiric acid reaction. Anal Biochem, 95 (2): 351-358, 1979.
22. Gundersen HJG, Jensen EB: The efficiency of systematic sampling in stereology and its prediction. J Microsc , 147 (3): 229-263, 1987.
23. Kneuertz PJ, Maithel SK, Staley CA, Kooby DA: Chemotherapy- associated liver injury: Impact on surgical management of colorectal cancer liver metastases: Review. Ann Surg Oncol, 18 (1): 181-190, 2011.
24. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropf M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol, 12 (5): 431-440, 2011.
25. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res, 61 (7): 3071-3076, 2001.
26. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kaufman M, Adams J, Schenkein DP, Anderson KC: A Phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 348 (26): 2609- 2617, 2003.
27. Rosiñol L, Montoto S, Cibeira MT, Bladé J: Bortezomib-induced severe hepatitis in multiple myeloma: A case report. Arch Intern Med, 165 (4): 464-5, 2005.
28. Kakar S: Acute Hepatitis-Nonspecific Reactive Hepatitis. In , Ferrell LD, Kakar S (Eds): Liver Pathology. 13-18, Demos Medical, New York, 2011.
29. Seaman WE, Ishak KG, Plotz PH: Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med , 80 (1): 1-8, 1974.
30. Kaplowitz, N: Drug-induced liver injury. Clin Infect Dis, 38 (2): 44-48, 2004.
31. Tujios S, Fontana RJ: Mechanisms of drug-induced liver injury: From bedside to bench: Review. Nat Rev Gastroenterol Hepatol, 8 (4): 202-211, 2011.
32. Pietraforte D, Vona R, Marchesi A, Tarissi de Jacobis I, Villani A, Del Principe D, Straface E: Redox control of platelet functions in physiology and pathophysiology. Antioxid Redox Signal, 2014 Apr 15. [Epub ahead of print]. DOI:10.1089/ARS.2013.5532.
33. Gardner HW: Oxygen radical chemistry of polyunsaturated fatty acids. Free Radic Biol Med, 7 (1): 65-86, 1989.
34. Jaeschke H, McGill MR, Ramachandran A: Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity: Review. Drug Metab Rev, 44 (1): 88-106, 2012.
35. VandenBerghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P: Regulated necrosis: The expanding network of non- apoptotic cell death pathways. Nat Rev Mol Cell Biol, 15(2): 135-147, 2014.
36. Guicciardi ME, Gores GJ: Apoptosis: A mechanism of acute and chronic liver injury: Review. Gut, 54 (7): 1024-1033, 2005.
37. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science, 274 (5291): 1379-1383, 1996.
38. Liu DF, Wei W, Song LH. Upregulation of TNF-alpha and IL-6 mRNA in mouse liver induced by bacilleCalmette-Guerin plus lipopolysaccharide. Acta Pharmacol Sin, 27 (4): 460-468, 2006.
39. Kim MJ, Lee SD, Kim DR, Kong YH, Sohn WS, Ki SS, Kim J, Kim YC, Han CJ, Lee JO, Nam HS, Park YH, Kim CH, Yi KH, Lee YY, Jeong SH: Use of complementary and alternative medicine among Korean cancer patients. Korean J Intern Med, 19 (4): 250-256, 2004.
40. Kim SY, Song HJ, Lee YY, Cho KH, Roh YK: Biomedical issues of dietary fiber β-glucan. J Korean Med Sci, 21 (5): 781-789, 2006.
41. Xia Y, Vetvicka V, Yan J, Hanikýrová M, Mayadas T, Ross GD: The b-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol, 162 (4): 2281-2290, 1999.
42. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, Ross GD: Beta-glucan, a specific biologic response modifier that uses anti- bodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol, 163 (6): 3045- 3052, 1999.
43. Delaney B, Carlson T, Frazer S, Zheng T, Hess R, Ostergren K, Kierzek K, Haworth J, Knutson N, Junker K, Jonker D: Evaluation of the toxicity of concentrated barley β-glucan in a 28-day feeding study in Wistar rats. Food Chem Toxicol 41, 477-487, 2002.
44. Kumtepe Y, Odabasoglu F, Karaca M, Polat B, Halici MB, Keles ON, Gocer F: Protective efects of telmisartan on ischemia/reperfusion injury of rat ovary: Biochemical and histopathologic evaluation. Fertil Steril, 93 (4): 1299-1307, 2010.
45. Halıcı M, Imik H, Koç M, Gümüş R: Efects of α-lipoic acid, vitamins E and C upon the heat stress in Japanese quails. J Anim Physiol Anim Nutr (Berl), 96 (3): 408-415, 2012.
46. Saluk-Juszczak J, Krolewska K, Wachowicz B: (1 →3)-β-D-Glucan inhibits a dual mechanism of peroxynitrite stroke. Int J Biol Macromol, 48 (3): 488-494, 2011.
47. Bayrak O, Turgut F, Karatas OF, Cimentepe E, Bayrak R, Catal F, Unal D: Oral β-glucan protects kidney against ischemia/reperfusion injury in rats. Am J Nephrol, 28 (2): 190-196, 2007.
48. Şener G, Toklu H, Ercan F, Erkanlı G: Protective effect of β-glucan against oxidative organ injury in a rat model of sepsis. Int Immunopharmacol, 5 (9): 1387- 1396, 2005.
49. Toklu HZ, Şener G, Jahovic N, Uslu B, Arbak S, Yeğen BÇ: β-glucan protects against burn-induced oxidative organ damage in rats. Int Immunopharmacol, 6 (2 ): 156-169, 2006.

APA	keleş o, CAN S, Çığşar G, ÇOLAK S, Erol H, AKARAS N, ERDEMCİ B, BİLGİN B, Can D, ÜNAL B, HALICI M (2014). Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats. , 929 - 938.
Chicago	keleş osman nuri,CAN Serpil,Çığşar Gülşen,ÇOLAK SUAT,Erol Huseyin Serkan,AKARAS Nurhan,ERDEMCİ Burak,BİLGİN Bülent Çağlar,Can Dr İsmail,ÜNAL Bünyami,HALICI Mesut Bünyamin Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats. (2014): 929 - 938.
MLA	keleş osman nuri,CAN Serpil,Çığşar Gülşen,ÇOLAK SUAT,Erol Huseyin Serkan,AKARAS Nurhan,ERDEMCİ Burak,BİLGİN Bülent Çağlar,Can Dr İsmail,ÜNAL Bünyami,HALICI Mesut Bünyamin Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats. , 2014, ss.929 - 938.
AMA	keleş o,CAN S,Çığşar G,ÇOLAK S,Erol H,AKARAS N,ERDEMCİ B,BİLGİN B,Can D,ÜNAL B,HALICI M Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats. . 2014; 929 - 938.
Vancouver	keleş o,CAN S,Çığşar G,ÇOLAK S,Erol H,AKARAS N,ERDEMCİ B,BİLGİN B,Can D,ÜNAL B,HALICI M Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats. . 2014; 929 - 938.
IEEE	keleş o,CAN S,Çığşar G,ÇOLAK S,Erol H,AKARAS N,ERDEMCİ B,BİLGİN B,Can D,ÜNAL B,HALICI M "Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats." , ss.929 - 938, 2014.
ISNAD	keleş, osman nuri vd. "Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats". (2014), 929-938.

APA	keleş o, CAN S, Çığşar G, ÇOLAK S, Erol H, AKARAS N, ERDEMCİ B, BİLGİN B, Can D, ÜNAL B, HALICI M (2014). Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, 20(6), 929 - 938.
Chicago	keleş osman nuri,CAN Serpil,Çığşar Gülşen,ÇOLAK SUAT,Erol Huseyin Serkan,AKARAS Nurhan,ERDEMCİ Burak,BİLGİN Bülent Çağlar,Can Dr İsmail,ÜNAL Bünyami,HALICI Mesut Bünyamin Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats. Kafkas Üniversitesi Veteriner Fakültesi Dergisi 20, no.6 (2014): 929 - 938.
MLA	keleş osman nuri,CAN Serpil,Çığşar Gülşen,ÇOLAK SUAT,Erol Huseyin Serkan,AKARAS Nurhan,ERDEMCİ Burak,BİLGİN Bülent Çağlar,Can Dr İsmail,ÜNAL Bünyami,HALICI Mesut Bünyamin Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, vol.20, no.6, 2014, ss.929 - 938.
AMA	keleş o,CAN S,Çığşar G,ÇOLAK S,Erol H,AKARAS N,ERDEMCİ B,BİLGİN B,Can D,ÜNAL B,HALICI M Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats. Kafkas Üniversitesi Veteriner Fakültesi Dergisi. 2014; 20(6): 929 - 938.
Vancouver	keleş o,CAN S,Çığşar G,ÇOLAK S,Erol H,AKARAS N,ERDEMCİ B,BİLGİN B,Can D,ÜNAL B,HALICI M Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats. Kafkas Üniversitesi Veteriner Fakültesi Dergisi. 2014; 20(6): 929 - 938.
IEEE	keleş o,CAN S,Çığşar G,ÇOLAK S,Erol H,AKARAS N,ERDEMCİ B,BİLGİN B,Can D,ÜNAL B,HALICI M "Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats." Kafkas Üniversitesi Veteriner Fakültesi Dergisi, 20, ss.929 - 938, 2014.
ISNAD	keleş, osman nuri vd. "Hepatoprotective effects of B-1,3-(D)-glucan on bortezomib-induced liver damage in rats". Kafkas Üniversitesi Veteriner Fakültesi Dergisi 20/6 (2014), 929-938.